TY - JOUR T1 - Adaptive Radiotherapy for Glioblastoma Multiforme – The Impact on Disease Outcome JF - Anticancer Research JO - Anticancer Res SP - 4237 LP - 4244 DO - 10.21873/anticanres.14425 VL - 40 IS - 8 AU - ZOLTÁN VÉGVÁRY AU - BARBARA DARÁZS AU - VIKTOR PACZONA AU - ÁGNES DOBI AU - ZITA REISZ AU - ZOLTÁN VARGA AU - EMESE FODOR AU - ADRIENN CSERHÁTI AU - JUDIT OLÁH AU - DÁVID KIS AU - PÁL BARZÓ AU - KATALIN HIDEGHÉTY Y1 - 2020/08/01 UR - http://ar.iiarjournals.org/content/40/8/4237.abstract N2 - Background/Aim: To study the changes of glioblastoma multiforme during chemoradiotherapy (CRT) and to evaluate the impact of changes on dosimetry and clinical outcomes. Patients and Methods: Forty-three patients underwent volumetric imaging-based replanning. Prognostic factors and gross tumor volume changes in relation to overall survival and the effect of adaptive replanning were statistically analyzed. Results: Patients with total tumor removal, with shorter time to CRT (<27 days), with methylated O-6 methylguanine DNA methyltransferase and good performance status (>60%) had better survival. Tumor shrinkage in 24 patients resulted in improved survival compared to 19 in whom tumor was unchanged or progressed (25.3 vs. 11.1 months, p=0.04). Adapted planning target volume allowed a reduction in irradiated volume, while increasing survival (12.06 vs. 28.98 months, p=0.026). Conclusion: Tumor response during CRT has significant impact on the outcome. Adaptation of the planning target volume to the tumor changes proved to be beneficial and warrants further investigation. ER -